GeneVentiv CEO: ‘We’re Giving Hope’ to Hemophilia A and B Patients With Inhibitors
An infusion of GENV-HEM results in endogenous expression of factor Va, which could improve homeostasis in patients with factor VIII or IX deficiency.
HEM Features
ATTR-CM Features, FA Features, Features, HEM Features, PNH Features, SCD Features, SM Features, SSc Features
Italian Hematologist Urges End to ‘Useless’ Restrictive Diets After Stem Cell Transplants
Hematologist Federico Stella, MD, says restrictive diets for patients in the hospital recovering from stem cell transplants are unnecessary.
Danny’s Dose Alliance Fights for Proper Emergency Care for Those With Bleeding Disorders
Danny’s Dose Alliance aims to “change current outdated emergency treatment protocols that affect the proper care of special needs medical patients.”
ANCA Features, ATTR-CM Features, CAD Features, CCA Features, CF Features, Features, GPP Features, HAE Features, HEM Features, IPF Features, LAL-D Features, LCFAOD Features, LGS Features, MDS Features, PNH Features, Pompe Features, SCD Features, SSc Features
At 40, Orphan Drug Act Enjoys Rare Bipartisan Support
Rare disease advocates are marking the 40th anniversary of the landmark Orphan Drug Act, which has led to over 1100 approvals for new therapies.
ALGS Features, ATTR-CM Features, DLBCL Features, DMD Features, Features, GPP Features, HEM Features, MDS Features, MG Features, NMOSD Features, PAH Features, PNH Features, Pompe Features, SM Features
Ambitious NCATS Bespoke Gene Therapy Consortium Targets Ultrarare Diseases
The Bespoke Gene Therapy Consortium (BGTC) is an ambitious public-private partnership that aims to develop gene therapies for ultrarare diseases.
AATD Features, CF Features, DMD Features, Features, GPP Features, HEM Features, IPF Features, LAL-D Features, LCFAOD Features, MG Features, MS Features, MTC Features, SCD Features, SMA Features
The Alliance for Regenerative Medicine Fights for Better Cell, Gene Therapies
The Alliance for Regenerative Medicine aims to help in the development of safe and effective regenerative therapies that can benefit rare disease patients.
Hemophilia May Benefit From Redosable Gene Therapy
Generation Bio is working to “create the next generation of gene therapy” that will enable the redosable, durable expression of missing proteins.
AATD Features, ALGS Features, CAD Features, CCA Features, CF Features, DMD Features, Features, GIST Features, HEM Features, IPF Features, LAL-D Features, LCFAOD Features, MG Features, NMOSD Features, PAH Features, Pompe Features, SCD Features, SMA Features
Israel Emerges as Global Powerhouse in Rare Disease Research
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
AATD Features, ALGS Features, CAD Features, CCA Features, CF Features, DMD Features, Features, GIST Features, HEM Features, Human Interest, IPF Features, LAL-D Features, LCFAOD Features, MG Features, MTC Features, PAH Features
NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses.
AATD Features, ALGS Features, CAD Features, CCA Features, DMD Features, Features, GIST Features, HEM Features, Human Interest, IPF Features, LAL-D Features, LCFAOD Features, MS Features, MTC Features, PAH Features
FDA, CDC Urge COVID-19 Vaccines for Rare Disease Patients on NORD Webinar
As the super-contagious Delta variant of COVID-19 sweeps across the globe, driving up infection rates as well as deaths, top US health officials are urging everyone 12 and older—including the country’s 30 million or so rare disease patients—to get vaccinated quickly.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Features
Loading... 
Loading...